Kosuke Kashiwabara1, Hiroshi Semba2, Shinji Fujii2, Shinsuke Tsumura2, Ryota Aoki2. 1. Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan kskkswbr@krmc.or.jp. 2. Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan.
Abstract
BACKGROUND: It is not clear whether there is a difference in benefit of chemotherapy between small cell lung cancer (SCLC) patients with pre-existing idiopathic interstitial pneumonias (IIPs) and non-small cell lung cancer (NSCLC) patients with IIPs. PATIENTS AND METHODS: We performed a retrospective study of the overall survival (OS) between advanced lung cancer patients with IIPs (n=28) and those without IIPs (n=145). RESULTS: The OS in NSCLC patients with IIPs was shorter than in those without IIPs (median OS, 10.6 vs. 27.9 months, p=0.008) but the OS in SCLC patients with IIPs was not inferior to that of those without IIPs (12.7 vs. 14.8 months, p=0.835). Multivariate analysis showed that the small number of regimens increased the risk of mortality, instead of pre-existing IIPs. CONCLUSION: The continuation of chemotherapy in SCLC patients with IIPs made it possible to have a similar prognosis to that in those without IIPs. Copyright
BACKGROUND: It is not clear whether there is a difference in benefit of chemotherapy between small cell lung cancer (SCLC) patients with pre-existing idiopathic interstitial pneumonias (IIPs) and non-small cell lung cancer (NSCLC) patients with IIPs. PATIENTS AND METHODS: We performed a retrospective study of the overall survival (OS) between advanced lung cancerpatients with IIPs (n=28) and those without IIPs (n=145). RESULTS: The OS in NSCLCpatients with IIPs was shorter than in those without IIPs (median OS, 10.6 vs. 27.9 months, p=0.008) but the OS in SCLCpatients with IIPs was not inferior to that of those without IIPs (12.7 vs. 14.8 months, p=0.835). Multivariate analysis showed that the small number of regimens increased the risk of mortality, instead of pre-existing IIPs. CONCLUSION: The continuation of chemotherapy in SCLCpatients with IIPs made it possible to have a similar prognosis to that in those without IIPs. Copyright
Authors: Myung Jin Song; Sung Yoon Lim; Jong Sun Park; Ho Il Yoon; Jae-Ho Lee; Song Yee Kim; Ji Ye Jung; Young Ae Kang; Moo Suk Park; Young Sam Kim; Joon Chang; Sang Hoon Lee; Choon-Taek Lee Journal: J Oncol Date: 2019-05-02 Impact factor: 4.375
Authors: Namrata Kewalramani; Carlos Machahua; Venerino Poletti; Jacques Cadranel; Athol U Wells; Manuela Funke-Chambour Journal: ERJ Open Res Date: 2022-06-20